Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes.

Galderisi A, Sherr J, VanName M, Carria L, Zgorski M, Tichy E, Weyman K, Cengiz E, Weinzimer S, Tamborlane W

The Journal of clinical endocrinology and metabolism1 Mar 2018Cited by 18 (Europe PMC)

PMID29211871PMCIDPMC6276715DOI10.1210/jc.2017-02265PepBankPUB-29211871

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanNon-randomized trialEfficacy outcome
In young adults with type 1 diabetes, 3 to 4 weeks of liraglutide had no effect on plasma glucagon responses during a mixed-meal tolerance test.
In plain wordsIn young adults with type 1 diabetes, 3 to 4 weeks of liraglutide did not change the glucagon rise after a meal.
Peptide
Liraglutide
Outcome
No significant changeMeal-stimulated plasma glucagon response
Study
n = 10
Comparator
Pretreatment
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 3 to 4 weeksAs given in this study (human).
Source sentences
Summary
In contrast, treatment with liraglutide had no effect on plasma glucagon and glucose responses during the MMTT.
1 context sentence(design, population, supporting numbers)
Summary · context
Two parallel studies were conducted in which participants underwent mixed-meal tolerance tests (MMTTs) without premeal bolus insulin administration before and after 3 to 4 weeks of treatment with either pramlintide (8 participants aged 20 ± 3 years, hemoglobin A1c 6.9 ± 0.5%) or liraglutide (10 part…
Report a problemFND-2921187101
02HumanNon-randomized trialEfficacy outcome
In young adults with type 1 diabetes, 3 to 4 weeks of liraglutide had no effect on plasma glucose responses during a mixed-meal tolerance test.
In plain wordsIn young adults with type 1 diabetes, 3 to 4 weeks of liraglutide did not change the blood sugar rise after a meal.
Peptide
Liraglutide
Outcome
No significant changeMeal-stimulated plasma glucose response
Study
n = 10
Comparator
Pretreatment
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 3 to 4 weeksAs given in this study (human).
Source sentences
Summary
In contrast, treatment with liraglutide had no effect on plasma glucagon and glucose responses during the MMTT.
1 context sentence(design, population, supporting numbers)
Summary · context
Two parallel studies were conducted in which participants underwent mixed-meal tolerance tests (MMTTs) without premeal bolus insulin administration before and after 3 to 4 weeks of treatment with either pramlintide (8 participants aged 20 ± 3 years, hemoglobin A1c 6.9 ± 0.5%) or liraglutide (10 part…
Report a problemFND-2921187102
03HumanNon-randomized trialMechanism
In participants with type 1 diabetes, pramlintide reduced the peak meal-stimulated glucagon increment compared with pretreatment.
In plain wordsIn participants with diabetes, pramlintide reduced the peak glucagon rise after meals compared with pretreatment.
Peptide
Pramlintide (Symlin)
Outcome
DecreasePeak glucagon increment
Study
n = 8
Comparator
Pretreatment mixed-meal tolerance test
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 3 to 4 weeksAs given in this study (human).
Measurements
Peak glucagon increment
32 pg/mL
pretreatment
Peak glucagon increment
23 pg/mL
pramlintide
P value
< 0.02
versus pretreatment
Source sentences
Summary
Compared with pretreatment responses to the MMTT, treatment with pramlintide reduced the peak increment in glucagon from 32 ± 16 to 23 ± 12 pg/mL (P < 0.02).
1 context sentence(design, population, supporting numbers)
Summary · context
Two parallel studies were conducted in which participants underwent mixed-meal tolerance tests (MMTTs) without premeal bolus insulin administration before and after 3 to 4 weeks of treatment with either pramlintide (8 participants aged 20 ± 3 years, hemoglobin A1c 6.9 ± 0.5%) or liraglutide
Report a problemFND-2921187103
04HumanNon-randomized trialMechanism
In participants with type 1 diabetes, pramlintide reduced incremental plasma glucagon area under the curve compared with pretreatment.
In plain wordsIn participants with diabetes, pramlintide reduced the overall glucagon rise after meals compared with pretreatment.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseIncremental plasma glucagon AUC
Study
n = 8
Comparator
Pretreatment mixed-meal tolerance test
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 3 to 4 weeksAs given in this study (human).
Measurements
Incremental glucagon AUC
1988 pg/mL/min
pretreatment
Incremental glucagon AUC
737 pg/mL/min
pramlintide
P value
< 0.001
versus pretreatment
Source sentences
Summary
In addition, the incremental area under the plasma glucagon curve from 0 to 120 minutes dropped from 1988 ± 590 to 737 ± 577 pg/mL/min (P < 0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
Two parallel studies were conducted in which participants underwent mixed-meal tolerance tests (MMTTs) without premeal bolus insulin administration before and after 3 to 4 weeks of treatment with either pramlintide (8 participants aged 20 ± 3 years, hemoglobin A1c 6.9 ± 0.5%) or liraglutide
Report a problemFND-2921187104
05HumanNon-randomized trialEfficacy outcome
In participants with type 1 diabetes, pramlintide reduced the meal-stimulated plasma glucose curve increment compared with pretreatment.
In plain wordsIn participants with diabetes, pramlintide reduced the overall blood sugar rise after meals compared with pretreatment.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseMeal-stimulated plasma glucose AUC increment
Study
n = 8
Comparator
Pretreatment mixed-meal tolerance test
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 3 to 4 weeksAs given in this study (human).
Measurements
Plasma glucose curve increment
11,963 mg/dL/min
pretreatment
Plasma glucose curve increment
2493 mg/dL/min
pramlintide
P value
< 0.01
versus pretreatment
Source sentences
Summary
which was accompanied by a similar reduction in the meal-stimulated increase in the plasma glucose curve from 11,963 ± 1424 mg/dL/min pretreatment vs 2493 ± 1854 mg/dL/min after treatment (P < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
Two parallel studies were conducted in which participants underwent mixed-meal tolerance tests (MMTTs) without premeal bolus insulin administration before and after 3 to 4 weeks of treatment with either pramlintide (8 participants aged 20 ± 3 years, hemoglobin A1c 6.9 ± 0.5%) or liraglutide
Report a problemFND-2921187105

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 8Current
28 Oct 2026, 02:03 UTC
The same notice was added 5 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.
Study results updated
Version 3
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 2
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.